EcoDrugPlus

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSLACG00000000291
Gene Symbol: PSMB1
4 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSLACG00000013849
Gene Symbol: PSMB10
4 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSLACG00000016163
Gene Symbol: PSMB2
4 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSLACG00000004652
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSLACG00000004161
Gene Symbol: PSMB4
4 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSLACG00000015194
Gene Symbol: PSMB5
4 Cross references
222 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSLACG00000001184
Gene Symbol: PSMB6
2 Cross references
242 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSLACG00000018747
Gene Symbol: PSMB7
4 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSLACG00000014047
Gene Symbol: PSMB8
4 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSLACG00000014279
Gene Symbol: PSMB9
4 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSLACG00000007998
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSLACG00000014095
Gene Symbol: PSMC1
4 Cross references
291 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).